Healthcare Resource Utilization and Costs Associated With Eosinophilic Esophagitis Among Commercially Insured Patients in the United States.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
24 Jun 2024
24 Jun 2024
Historique:
received:
20
12
2023
accepted:
11
06
2024
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
aheadofprint
Résumé
To evaluate real-world healthcare resource utilization (HCRU) and costs associated with eosinophilic esophagitis (EoE) in the United States. Retrospective case-control cohort analysis of Optum Clinformatics claims data (January 2008-September 2020) comparing unadjusted and adjusted HCRU (visits per 1,000 patients per month) and all-cause costs (per patient per month). Patients with EoE incurred significantly higher monthly HCRU (adjusted Δ [95% confidence interval]: inpatient visits, 2.8 [0.1-4.0]; emergency department visits, 14.7 [4.3-32.1]; outpatient visits, 388.8 [362.1-418.0]); and costs ($581 [$421-$600]) vs matched controls (all P < 0.001). EoE imposes substantial economic burden. More effective and targeted treatments that improve outcomes for patients are needed.
Identifiants
pubmed: 39007710
doi: 10.14309/ajg.0000000000002901
pii: 00000434-990000000-01202
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bristol Myers Squibb
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Hahn JW, Lee K, Shin JI, et al. Global incidence and prevalence of eosinophilic esophagitis, 1976-2022: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2023;21(13):3270–84.e77.
Bredenoord AJ, Patel K, Schoepfer AM, et al. Disease burden and unmet need in eosinophilic esophagitis. Am J Gastroenterol 2022;117(8):1231–41.
Dellon ES. Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol 2019;123(2):166–72.
Eke R, Dellon ES. Hospitalization trends and determinants of inpatient costs for eosinophilic esophagitis patients in the United States: Results from the Nationwide Inpatient Sample analysis. Ann Gastroenterol 2021;34(5):643–50.
Jensen ET, Kappelman MD, Martin CF, et al. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol 2015;110(5):626–32.
Lu M, Goodwin B, Vera-Llonch M, et al. Disease burden and treatment patterns associated with eosinophilic esophagitis in the United States: A retrospective claims study. J Clin Gastroenterol 2022;56(2):133–40.
Mukkada V, Falk GW, Eichinger CS, et al. Health-related quality of life and costs associated with eosinophilic esophagitis: A systematic review. Clin Gastroenterol Hepatol 2018;16(4):495–503.e8.
Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology 2019;156(1):254–72.e11.
US Bureau of Labor Statistics. Consumer Price Index (https://www.bls.gov/cpi/). Accessed February 5, 2024.
Chehade M, Epstein AJ, McCann E, et al. Health care resource utilization and costs among eosinophilic esophagitis patients in the United States. Am J Gastroenterol 2022;117(10S):e274–5.
Solanki S, Haq KF, Khan MA, et al. Trends of eosinophilic esophagitis in the US inpatient population. Gastroenterology 2017;152(5; Suppl 1):S873.
Brook RA, Wahlqvist P, Kleinman NL, et al. Cost of gastro-oesophageal reflux disease to the employer: A perspective from the United States. Aliment Pharmacol Ther 2007;26(6):889–98.
Sheedy K, Patel N, Porter J, et al. Cost and accessibility of empiric food elimination diets for treatment of eosinophilic oesophagitis. Nutr Diet 2022;79(2):238–46.
Joshi S, Rubenstein JH, Dellon ES, et al. Variability in practices of compounding budesonide for eosinophilic esophagitis. Am J Gastroenterol 2021;116(6):1336–8.
Fan TA, Aggarwal J, Jiang J, et al. S390 Estimating the indirect and intangible costs associated with eosinophilic esophagitis. Am J Gastroenterol 2021;116(1):S171–2.